By FieldPulse Editorial · March 25, 2026
Tags: GLP-1, Clinical Trials, Pipeline
Novo Nordisk's triple-G agonist — targeting GLP-1, GIP, and glucagon receptors — has produced competitive results in a midphase diabetes trial, adding to an intensifying post-semaglutide rivalry with Eli Lilly in the next-generation metabolic class.
Novo Nordisk's triple-G agonist, a next-generation metabolic drug targeting GLP-1, GIP, and glucagon receptors simultaneously, has cleared a midphase diabetes trial in China with competitive results, the company announced Wednesday. The data add another data point to one of the most consequential races in pharmaceutical development: who follows semaglutide, and with what. Triple-G agonists represent a step beyond the dual-agonist class that Eli Lilly currently leads with tirzepatide. By adding glucagon receptor activation to the GLP-1 and GIP combination, these drugs aim to drive additional me